
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en-us" lang="en-us" id="no-js">
<head>
<meta content="Percussion CM System" name="generator"/>
<meta name="perc_linkback" id="perc_linkback" content="FmRmZWdtZXgHZ2F4AWNhYngGZmVgeBNsbWVsYQ=="/><!-- Internal Release Version # 3.6.3 -->
<meta http-equiv="X-UA-Compatible" content="IE=edge" />
<meta http-equiv="content-type" content="text/html; charset=utf-8" />
<meta name="description" content="This page explains evaluating and updating immunizations during the domestic medical examination for newly arrived refugees." /><meta name="keywords" content="Immigrant and Refugee Health, Refugee and Immigrant Health, Technical instructions for medical examination of immigrants and refugees, Medical examination of immigrants and refugees, Civil surgeon, Panel physician, Medical screening, Alien, Aliens, Immigration, Refugee resettlement, TB screening of immigrants and refugees, Tuberculosis screening of immigrants and refugees" /><meta name="DC.Language" scheme="ISO 639-1" content="en-us" />
<meta name="template.version" content="2.7.0" />
<meta name="cdc:content-id" content="130280"/>
<meta name="cdc:revision-id" content="24"/>

<link rel="canonical" href="http://www.cdc.gov/immigrantrefugeehealth/guidelines/overseas/intestinal-parasites-overseas.html"/>
<title>Overseas Intestinal Parasites Guidelines | Immigrant and Refugee Health | CDC</title>


<link rel="stylesheet" href="../../../TemplatePackage/css/B/reset.css" type="text/css" media="screen" />
<link rel="stylesheet" href="../../../TemplatePackage/css/B/newMods.css" type="text/css" media="screen" />
<link rel="stylesheet" href="../../../TemplatePackage/css/B/print.css" type="text/css" media="print" />

<!-- compliance patch for microsoft browsers -->
<!--[if IE 6]>
<link rel="stylesheet" type="text/css" href="/TemplatePackage/css/B/ie6_fixes.css" />
<![endif]-->

<!--[if IE 7]>
<link rel="stylesheet" type="text/css" href="/TemplatePackage/css/B/ie7_fixes.css" />
<![endif]-->

<!--[if IE 8]>
<link rel="stylesheet" type="text/css" href="/TemplatePackage/css/B/ie8_fixes.css" />
<![endif]-->
<!-- /end compliance patch for microsoft browsers -->

<script type="text/javascript">(function(H){H.id=H.id.replace('no-','')})(document.documentElement)</script>

<script type="text/javascript" src="../../../TemplatePackage/js/B/jquery.js"></script>
<script type="text/javascript" src="../../../TemplatePackage/js/B/jquery.watermark.js"></script>
<script type="text/javascript" src="../../../TemplatePackage/js/B/common.js"></script>
<script type="text/javascript" src="../../../TemplatePackage/js/B/startup.js"></script>
<script type="text/javascript" src="../../../TemplatePackage/js/B/socialMedia.js"></script>
<script type="text/javascript" src="../../../TemplatePackage/js/B/blocks-ie.js"></script>
<script type="text/javascript" src="../../../TemplatePackage/js/B/video.js"></script>
<script type="text/javascript" src="../../../TemplatePackage/js/B/navScripts.js"></script>
<script type="text/javascript" src="../../../TemplatePackage/js/B/govdelivery.js"></script>
<script type="text/javascript" src="../../../TemplatePackage/js/B/anchor.js"></script>
<script type="text/javascript" src="../../../TemplatePackage/js/B/syndicateThisPage.js"></script>
<script type="text/javascript" src="../../../TemplatePackage/js/B/css-include.js"></script>
<script type="text/javascript" src="../../../TemplatePackage/3.0/js/libs/moment/moment.min.js"></script>

<!-- compliance patch for microsoft browsers -->
<!--[if IE 6]>
<script type="text/javascript" src="/TemplatePackage/js/B/pngfix.js"></script>
<script type="text/javascript" src="/TemplatePackage/js/B/blocks-ie6.js"></script>
<![endif]-->

<!--[if IE 7]>
<link rel="stylesheet" type="text/css" href="/TemplatePackage/css/B/ie7_fixes.css" />
<script type="text/javascript" src="/TemplatePackage/js/B/cdc-curvyCompatibility.js"></script>
<![endif]-->

<!--[if lte IE 8]>
<script type="text/javascript" src="/TemplatePackage/js/B/jquery.curvycorners.js"></script>
<![endif]-->

<script type="text/javascript" src="../../../TemplatePackage/js/B/cdc-gridCompatibility.js"></script>

<link rel="shortcut icon" href="../../../TemplatePackage/images/home/favicon.ico" />
<link rel="home" href="../../../index.html" title="Home" />

      <style type="text/css">@import "../../../~inc~/globalwcmscss.css";</style>
  
	



<!-- Begin Survey scripts --> 
<script type="text/javascript" src="../../../JScript/foresee/foresee-trigger.js"></script> 
<script type="text/javascript" src="../../../JScript/foresee-variables.js"></script> 
<!-- End Survey scripts -->







<!--[if IE]>
<script defer language="javascript" type="text/javascript">
		var cdcLeftNav = new CDC.LeftNav("nav-primary", location.pathname, false, true);
		cdcLeftNav.render();
</script>
<![endif]-->
<!--[if ! IE]><!-->
<script language="javascript" type="text/javascript">
$().ready(function(){
		var cdcLeftNav = new CDC.LeftNav("nav-primary", location.pathname, false, true);
		cdcLeftNav.render();
});
</script>
<!--<![endif]-->



  <style type="text/css">  </style> <script type="text/javascript">(function(H){H.id=H.id.replace('no-','')})(document.documentElement)</script>
      <style type="text/css">@import "../../~inc~/local.css";</style>
  </head>
<body id="contentPageStandard" class="secondTier localSearch wcms v270 ">
<div id="skipmenu">
	<a href="intestinal-parasites-overseas.html#searchCDC" class="skippy" title="Skip to search">Skip directly to search</a> 
	<a href="intestinal-parasites-overseas.html#az" class="skippy" title="Skip to A to Z list">Skip directly to A to Z list</a> 
	<a href="intestinal-parasites-overseas.html#nav" class="skippy" title="Skip to navigation">Skip directly to navigation</a> 
	<a href="intestinal-parasites-overseas.html#content" class="skippy" title="Skip to content">Skip directly to site content</a> 
	<a href="intestinal-parasites-overseas.html#content-secondary" class="skippy" title="Skip to page options">Skip directly to page options</a>
</div>  
<div id="wrapper">
	<div id="wrapper-inner">
		<div id="branding">
            

<span id="homeward"><a href="../../../index.html" title="Return to the CDC Home Page">CDC Home</a></span>
<div id="branding-logo">
	<div id="branding-logoImage"><img src="../../../TemplatePackage/images/cdcHeaderLogo.gif" width="470" height="47" align="left" alt="CDC. Centers for Disease Control and Prevention. CDC 24/7: Saving Lives. Protecting People." border="0" /><a href="../../../index.html" title="CDC 24/7: Saving Lives. Protecting People.&trade;"><span>CDC 24/7: Saving Lives. Protecting People.&trade;</span></a></div>
	

            


 <div id="searchForm" class="searchResize"><a name="search"></a>
		<form id="searchCDC" method="get" action="http://search.cdc.gov/search">
			<fieldset>
				<div id="cdc-Query">                                                
					<label for="searchBox" class="overlabel search">Search The CDC</label>
					<input id="searchBox" class="searchBox" name="query" maxlength="256" type="text" />
				</div>
				<div id="cdc-Submit">
					<!--<label for="searchButton" class="searchButton">Search Button</label>-->
					<input id="searchButton" class="searchButton" src="../../../TemplatePackage/images/home/search_button.gif" name="searchButton" alt="Search" type="image" />
					<input name="action" value="search" type="hidden" />
		                                                      <input type="hidden" name="utf8" value="&#x2713;" />
		                                                      <input type="hidden" name="affiliate" value="cdc-main" />
				</div>
			</fieldset>
		</form>
	</div>
</div>

             <noscript>
<div class="noscript"> Note: Javascript is disabled or is not supported by your browser. For this reason, some items on this page will be unavailable. For more information about this message, please visit this page: <a href="../../../Other/about_cdcgov.html" title="Browser requirements for CDC.gov">About CDC.gov</a>.</div>
</noscript>


		</div>
		<div id="content">
			<div id="topic-title">
				<h2>


<a href="../../index.html">Immigrant and Refugee Health</a>

</h2>
			</div>				
			<div id="content-inner">
				<!--BREADCRUMBS START HERE-->
				<div id="breadBox"><ul id="breadcrumbs"><li style=" display: none;"> </li></ul></div> 									


<div id="socialMediaContainer">
	<div class="share_container noLinking">
	 	<a class="share_button_facebook" title="Facebook" href="intestinal-parasites-overseas.html#"><span id="share_facebook" class="facebookRecommend"></span></a>
	 	<a class="share_button_twitter" title="Twitter" href="intestinal-parasites-overseas.html#"><span id="share_twitter" class="twitterTweet"></span></a>
		<a class="share_button noLinking" href="intestinal-parasites-overseas.html#socialMediaShareContainer"><img src="../../../TemplatePackage/3.0/images/sm-plus.gif" alt="Share" /><span class="shareButtonEn">Share</span><span class="shareButtonEs">Compartir</span></a>
	</div>
</div>


								<div id="content-main" >
					<div class="main-inner">						
					
											<div class='syndicate'>
																<div class='mSyndicate'>
											<h1>Guidelines for Overseas Presumptive Treatment of Strongyloidiasis, Schistosomiasis, and Soil-Transmitted Helminth Infections </h1>
                        												</div>
																</div>
																																		                                                    				                                                                        				                                    <div class="subColumns">
                    <div class="subc">
                                                                                
			<div class="syndicate">
<div class="mSyndicate">
    <div class="module rounders" >
      <div class="inner">		
				<div class="subColumns">
		  <div class="subc">
        	<p>
  	    	    	    	            <a href="https://www.cdc.gov/immigrantrefugeehealth/pdf/intestinal-parasites-overseas.pdf">PDF version of these guidelines for printing     		    			[PDF - 12 pages]
    		    	  </a>
	  </p>
					  </div>
		</div>
	  </div>
	</div>
	</div>
</div>
                                                      </div>
                    </div>
                                				            				                                                                        				                                    <div class="subColumns">
                    <div class="subc">
                                                                                
			<div class="syndicate">
<div class="mSyndicate">
    <div class="module page-curl bulleted-links in-link" >
      <div class="inner">		
		<h3>UPDATES--the following are content updates from the previous version of the overseas guidance, which was posted in 2008</h3>
		<div class="subColumns">
		  <div class="subc">
        	<ul><li>Latin American and Caribbean refugees are now included, in addition to Asian, Middle Eastern, and African refugees.</li><li>Recommendations for management of <em>Strongyloides</em> in refugees from <em>Loa loa</em>-endemic areas emphasize a screen-and-treat approach and de-emphasize a presumptive high-dose albendazole approach.</li><li>Presumptive use of albendazole during any trimester of pregnancy is no longer recommended.</li><li>Links to a new table for the <a href="https://www.cdc.gov/immigrantrefugeehealth/guidelines/overseas/interventions.html">Treatment Schedules for Presumptive Parasitic Infections for U.S.-Bound Refugees</a>, administered by IOM.</li></ul>
					  </div>
		</div>
	  </div>
	</div>
	</div>
</div>
                                                      </div>
                    </div>
                                				            				                                                                        				                                    <div class="subColumns">
                    <div class="subc">
                                                                                
			<div class="syndicate">
<div class="mSyndicate">
    <div class="module rounders bulleted-links alt-toc" >
      <div class="inner">		
		<h3>Contents</h3>
		<div class="subColumns">
		  <div class="subc">
        	<div class="twoColumn"><div class="c50l columns"><div class="subcl"><h5><a href="intestinal-parasites-overseas.html#summary">Summary of Recommendations</a></h5><h5><a href="intestinal-parasites-overseas.html#background">Background</a></h5><h5><a href="intestinal-parasites-overseas.html#overseas-presumptive-treatment">Recommendations for overseas presumptive treatment of intestinal parasites</a></h5><ul><li><a href="intestinal-parasites-overseas.html#me-asia-na-la-caribbean">Refugees originating from the Middle East, Asia, North Africa, Latin America, and the Caribbean</a></li><li><a href="intestinal-parasites-overseas.html#sub-saharan-africa">Refugees originating from sub-Saharan Africa</a></li><li><a href="intestinal-parasites-overseas.html#special-instructions">Special instructions for administration of presumptive pre-departure therapy</a></li></ul></div></div><div class="c50r columns"><div class="subcr"><h5><a href="intestinal-parasites-overseas.html#precautions">Precautions and contraindications to presumptive treatment</a></h5><ul><li><a href="intestinal-parasites-overseas.html#children">Children</a></li><li><a href="intestinal-parasites-overseas.html#pregnant-women">Pregnant women</a></li><li><a href="intestinal-parasites-overseas.html#breastfeeding">Women who are breastfeeding</a></li><li><a href="intestinal-parasites-overseas.html#cysticercosis-infection">Refugees with cysticercosis infection</a></li></ul><h5><a href="intestinal-parasites-overseas.html#documentation">Documentation</a></h5><h5><a href="intestinal-parasites-overseas.html#references">References</a></h5><h5><a href="intestinal-parasites-overseas.html#table-1">Table 1</a></h5><h5><a href="intestinal-parasites-overseas.html#table-2">Table 2</a></h5><h5><a href="intestinal-parasites-overseas.html#table-3">Table 3</a></h5><h5><a href="intestinal-parasites-overseas.html#box-1">Box 1</a></h5></div></div></div>
					  </div>
		</div>
	  </div>
	</div>
	</div>
</div>
                                                      </div>
                    </div>
                                				                                        											<div class='syndicate'>
																<div class='mSyndicate'>
															<h2><a class="onThisPageAnchor" id="summary" name="summary" title="&lt;strong&gt;Summary of Recommendations&lt;/strong&gt;"></a>Summary of Recommendations</h2><p>These guidelines are recommendations for the International Organization for Migration (IOM) physicians and other panel physicians who administer overseas predeparture presumptive treatment for intestinal parasites. While most recommendations have been implemented, not all refugee populations listed in this document are receiving all recommended pre-departure medications, due to funding restrictions and logistical challenges. For current implementation status in specific populations, see the <a href="https://www.cdc.gov/immigrantrefugeehealth/guidelines/overseas/interventions.html">Treatment Schedules for Presumptive Parasitic Infections for U.S.-Bound Refugees, administered by IOM</a>. The recommendations in these guidelines may also be used by U.S. medical providers caring for refugees who will be receiving presumptive treatment after they arrive in the United States.</p><ul><li>All Middle Eastern, Asian, North African, Latin American, and Caribbean refugees, with exceptions noted in this document, should receive presumptive therapy with: <ul><li>Albendazole, single dose of 400 mg (200 mg for children 12-23 months) AND</li><li>Ivermectin, two doses 200 &#181;/Kg orally once a day for 2 days before departure to the United States.</li></ul></li><li>All African refugees who did not originate from or reside in countries where <em>Loa loa</em> infection is endemic (<a href="intestinal-parasites-overseas.html#box-1">Box 1</a>), with exceptions noted in this document, should receive presumptive therapy with: <ul><li>Albendazole, single dose of 400 mg (200 mg for children 12-23 months) AND</li><li>Ivermectin, two doses 200 &#181;/Kg orally once a day for 2 days AND</li><li>Praziquantel, 40 mg/kg, which may be divided in two doses before refugees depart for the United States.</li></ul></li><li>All sub-Saharan African refugees who originated from or resided in countries where <em>Loa loa</em> infection is endemic (<a href="intestinal-parasites-overseas.html#box-1">Box 1</a>), with exceptions noted in this document, should receive presumptive therapy with: <ul><li>Albendazole, single dose of 400 mg (200 mg for children 12-23 months) AND</li><li>Praziquantel, 40 mg/kg, which may be divided in two doses before departure to the United States.</li><li>Refugees from <em>Loa loa</em>-endemic countries (<a href="intestinal-parasites-overseas.html#box-1">Box 1</a>) in Africa should not receive presumptive ivermectin for strongyloidiasis prior to departure. Management of <em>Strongyloides</em> should be deferred until arrival in the United States, unless <em>Loa loa</em> is excluded by reviewing a daytime (10 AM to 2 PM) Giemsa-stained blood smear. Deferral of treatment for strongyloides until after the refugee arrives in the United States is acceptable. Guidance is available for management of <em>Strongyloides</em> following arrival in the United States in the Domestic Intestinal Parasite Screening <a href="../domestic/intestinal-parasites-domestic.html">Guidelines</a>.</li></ul></li></ul><h2><a class="onThisPageAnchor" id="background" name="background" title="&lt;strong&gt;Background&lt;/strong&gt;"></a>Background</h2><p>In 1997, a Centers for Disease Control and Prevention (CDC) pilot project evaluated single-dose albendazole presumptive treatment in U.S.-bound Barawan Somali refugees.<sup><a href="intestinal-parasites-overseas.html#ref-1">1</a></sup> This project demonstrated decreases in soil-transmitted parasites in refugees who received presumptive treatment. In May 1999, CDC extended this recommendation to all refugees resettling from sub-Saharan Africa (SSA) and Asia. In 2008 the recommendation was extended to refugees from the Middle East. Currently, most refugees from the countries listed in the <a href="https://www.cdc.gov/immigrantrefugeehealth/guidelines/overseas/interventions.html">Treatment Schedules for Presumptive Parasitic Infections for U.S.-Bound Refugees</a> and without a contraindication are receiving a single dose of albendazole prior to departure.</p><p>Data increasingly suggest that pre-departure albendazole treatment has dramatically decreased the overall prevalence of soil-transmitted helminth infections in refugees. A recent evaluation of more than 26,000 African and Asian refugees demonstrated single-dose albendazole resulted in an absolute reduction of the prevalence of any soil-transmitted helminth from 20.8% to 4.7%, as measured by stool ova and parasite examination.<sup><a href="intestinal-parasites-overseas.html#ref-2">2</a></sup> These findings support previous data in African refugees resettling to the United States, showing a similar decrease in soil-transmitted helminths following implementation of pre-departure albendazole treatment.<sup><a href="intestinal-parasites-overseas.html#ref-3">3</a></sup> Despite this documented decrease in the overall prevalence of soil-transmitted helminth infections, a single dose of albendazole has very limited effect on infection with <em>Strongyloides</em> and no effect against <em>Schistosoma</em> spp.<sup><a href="intestinal-parasites-overseas.html#ref-2">2</a>, <a href="intestinal-parasites-overseas.html#ref-4">4</a>, <a href="intestinal-parasites-overseas.html#ref-5">5</a></sup></p><p>Due to documented high rates of infection in refugee populations and increasing reports of serious clinical consequences, in 2005 CDC issued recommendations for pre-departure treatment for strongyloidiasis (in all Middle Eastern, Asian, and African refugees) as well as for schistosomiasis (in SSA refugees only). This document is an update of the 2005 guidelines.</p><h2><a class="onThisPageAnchor" id="overseas-presumptive-treatment" name="overseas-presumptive-treatment" title="&lt;strong&gt;Recommendations for overseas presumptive treatment of intestinal parasites&lt;/strong&gt;"></a>Recommendations for overseas presumptive treatment of intestinal parasites</h2><h3><a class="onThisPageAnchor" id="me-asia-na-la-caribbean" name="me-asia-na-la-caribbean" title="&lt;em&gt;Refugees originating from the Middle East, Asia, North Africa, Latin America, and the Caribbean&lt;/em&gt;"></a>Refugees originating from the Middle East, Asia, North Africa, Latin America, and the Caribbean</h3><p>Prior to departure for the United States, all refugees originating from the Middle East, Asia, North Africa, Latin American, &amp; Caribbean, with exceptions noted in this document, should receive presumptive therapy with ivermectin for <em>Strongyloides</em> infection and with albendazole for infections caused by soil-transmitted helminths (<a href="intestinal-parasites-overseas.html#table-1">Table 1</a>). Dosing for ivermectin may be based on weight and available tablet size (<a href="intestinal-parasites-overseas.html#table-2">Table 2</a>).</p><h3><a class="onThisPageAnchor" id="sub-saharan-africa" name="sub-saharan-africa" title="&lt;em&gt;Refugees originating from sub-Saharan Africa&lt;/em&gt;"></a>Refugees originating from sub-Saharan Africa</h3><h4>Soil-transmitted helminths</h4><p>All refugees originating from sub-Saharan Africa should receive presumptive therapy with albendazole for infections caused by soil-transmitted helminths (<a href="intestinal-parasites-overseas.html#table-1">Table 1</a>).</p><h4><em>Strongyloides</em></h4><p>Refugees from sub-Saharan Africa should also receive presumptive therapy for <em>Strongyloides</em> infection with ivermectin (<a href="intestinal-parasites-overseas.html#table-1">Table 1</a>), but this will depend on whether they have originated from or resided in countries where <em>Loa loa</em> is endemic (<a href="intestinal-parasites-overseas.html#box-1">Box 1</a>).The drug of choice for <em>Strongyloides</em> infection is ivermectin. However, cases of encephalopathy have occurred in patients treated with ivermectin during large-scale public health campaigns in areas of Africa where <em>Loa loa</em> is endemic. Although rare, this reaction is related to <em>Loa loa</em> microfilarial load. Therefore, ivermectin should be given only to persons originating from Africa who have resided in or come from countries or areas not considered endemic for <em>Loa loa</em> (<a href="intestinal-parasites-overseas.html#box-1">Box 1</a>). Sub-Saharan African refugees who have resided in or are coming from areas endemic for <em>Loa loa</em> should <em>not</em> receive presumptive ivermectin, and management of <em>Strongyloides</em> should be deferred until they arrive in the United States (unless <em>Loa loa</em> is excluded by reviewing a daytime [10 AM to 2 PM] Giemsa-stained blood smear). High-dose albendazole (400 mg twice a day for 7 days) is an acceptable alternative if <em>Loa loa</em> infection cannot be excluded.</p><h4>Schistosomiasis</h4><p>Refugees from sub-Saharan Africa should also receive presumptive pre-departure therapy with praziquantel for schistosomiasis (<a href="intestinal-parasites-overseas.html#table-1">Table 1</a>). Pre-departure dosing may be based on weight and available tablet size (<a href="intestinal-parasites-overseas.html#table-2">Table 2</a>). If the refugee has never received presumptive therapy as part of a mass anti-helminth treatment campaign, and if it is logistically feasible, administering praziquantel first, followed by albendazole and ivermectin, may reduce the risk of adverse events caused by the release of antigens by dying parasites in persons with high parasite loads. However, if the refugee has received previous therapy, their parasite load can be assumed to be lower, and there would be no contraindication to administering praziquantel together with albendazole and ivermectin.</p><h3><a class="onThisPageAnchor" id="special-instructions" name="special-instructions" title="&lt;em&gt;Special instructions for administration of presumptive pre-departure therapy&lt;/em&gt;"></a>Special instructions for administration of presumptive pre-departure therapy</h3><ul><li>Pre-departure regimens for presumptive treatment of intestinal parasites should be administered as directly observed therapy. While prescription and first-dose observation should be done by medical personnel, subsequent doses can be observed by nonmedical staff.</li><li>Pregnancy testing should be performed before ivermectin or albendazole is administered.</li><li>Ivermectin and albendazole may be administered concurrently according to World Health Organization (WHO) recommendations. In areas where refugees have received previous rounds of mass anti-helminth treatment, ivermectin, albendazole, and praziquantel co-administration is well tolerated.<sup><a href="intestinal-parasites-overseas.html#ref-6">6</a></sup></li><li>Praziquantel may be better tolerated if divided into two doses.</li><li>There is no known contraindication to co-administration of these intestinal treatment regimens with malaria treatment medications. When time allows, spacing may improve tolerability. A sample 3-day combined treatment regimen for both parasites and malaria is presented in <a href="intestinal-parasites-overseas.html#table-3">Table 3</a>.</li></ul><h2><a class="onThisPageAnchor" id="precautions" name="precautions" title="&lt;strong&gt;Precautions and contraindications to presumptive treatment&lt;/strong&gt;"></a>Precautions and contraindications to presumptive treatment</h2><h3><a class="onThisPageAnchor" id="children" name="children" title="&lt;em&gt;Children&lt;/em&gt;"></a>Children</h3><h4>Albendazole</h4><p>Children &lt;1 year of age should not receive presumptive treatment with albendazole. Further information on use of albendazole in pediatric patients can be found at the <a href="http://www.cdc.gov/parasites/strongyloides/health_professionals/">CDC, Division of Parasitic Diseases website</a>.</p><h4>Ivermectin</h4><p>Children weighing &lt;15 kg or measuring &lt;90 cm should not receive presumptive treatment with ivermectin. Further information on use of ivermectin in pediatric patients can be found at the <a href="http://www.cdc.gov/parasites/strongyloides/health_professionals/">CDC, Division of Parasitic Diseases website</a>.</p><h4>Praziquantel</h4><p>The safety of praziquantel has not been established in children &lt;4 years of age or &lt;94 cm in height, so these children should not receive presumptive treatment. Further information on use of praziquantel in pediatric patients can be found at the <a href="http://www.cdc.gov/parasites/schistosomiasis/health_professionals/">CDC, Division of Parasitic Diseases website</a>.</p><h3><a class="onThisPageAnchor" id="pregnant-women" name="pregnant-women" title="&lt;em&gt;Pregnant women&lt;/em&gt;"></a>Pregnant women</h3><h4>Albendazole</h4><p>Albendazole is currently a category C drug in the United States, and it should not be administered as presumptive treatment for U.S.-bound refugees during any trimester of pregnancy. When a reliable history of the woman&#39;s last menstrual period cannot be obtained, a pregnancy test should be performed. Pregnant women should have presumptive treatment deferred until after they arrive in the United States. Further information on use of albendazole during pregnancy can be found at the <a href="http://www.cdc.gov/parasites/strongyloides/health_professionals/">CDC, Division of Parasitic Diseases website</a>.</p><h4>Ivermectin</h4><p>Ivermectin is a pregnancy category C drug. This medication should not be administered as a presumptive medication to a pregnant woman. When a reliable history of the woman&#39;s last menstrual period cannot be obtained, a pregnancy test should be performed before presumptive treatment is administered. Further information on use of ivermectin during pregnancy can be found at the <a href="http://www.cdc.gov/parasites/strongyloides/health_professionals/">CDC, Division of Parasitic Diseases website</a>.</p><h4>Praziquantel</h4><p>Praziquantel is considered a pregnancy category B drug, and WHO recommends the presumptive treatment of pregnant women during any trimester of pregnancy in women from schistosomiasis-endemic areas. Further information on use of praziquantel during pregnancy can be found at the <a href="http://www.cdc.gov/parasites/schistosomiasis/health_professionals/">CDC, Division of Parasitic Diseases website</a>.</p><h3><a class="onThisPageAnchor" id="breastfeeding" name="breastfeeding" title="&lt;em&gt;Women who are breastfeeding&lt;/em&gt;"></a>Women who are breastfeeding</h3><h4>Albendazole</h4><p>Albendazole presumptive therapy may be administered to women who are breastfeeding. Further information on use of albendazole during lactation can be found at the <a href="http://www.cdc.gov/parasites/strongyloides/health_professionals/">CDC, Division of Parasitic Diseases website</a>.</p><h4>Ivermectin</h4><p>Ivermectin should not be administered to women who are breastfeeding during the first week after birth. Further information on use of ivermectin during lactation can be found at the <a href="http://www.cdc.gov/parasites/strongyloides/health_professionals/">CDC, Division of Parasitic Diseases website</a>.</p><h4>Praziquantel</h4><p>Praziquantel is excreted in low concentrations in human milk. According to WHO guidelines for mass prevention campaigns, the use of praziquantel during lactation is encouraged.<sup><a href="intestinal-parasites-overseas.html#ref-7">7</a></sup> For individual patients in clinical settings, praziquantel should be used in breast-feeding women only when the risk to the infant is outweighed by the risk of disease progression in the mother in the absence of treatment. Further information on use of praziquantel during lactation can be found at the <a href="http://www.cdc.gov/parasites/schistosomiasis/health_professionals/">CDC, Division of Parasitic Diseases website</a>.</p><h3><a class="onThisPageAnchor" id="cysticercosis-infection" name="cysticercosis-infection" title="&lt;em&gt;Refugees with cysticercosis infection&lt;/em&gt;"></a>Refugees with cysticercosis infection</h3><p>Persons who have neurocysticercosis infection may have seizures following treatment with albendazole or praziquantel, since these medications kill <em>Taenia solium</em> cysticerci, causing inflammation and provoking seizure activity in the brain. The true prevalence of neurocysticercosis in refugee populations is not well documented. Confirmed case reports of adverse events after treatment with albendazole or praziquantel remain rare in refugees. Refugees with known neurocysticercosis, an unexplained seizure disorder, or subcutaneous nodules consistent with cystercercosis should not receive presumptive treatment with either albendazole or praziquantel.</p><p>Physicians should consult the package inserts for additional information about ivermectin, albendazole, and praziquantel.</p><h2><a class="onThisPageAnchor" id="documentation" name="documentation" title="&lt;strong&gt;Documentation&lt;/strong&gt;"></a>Documentation</h2><p>Test results and pre-departure treatment should be documented on the Predeparture Medical Screening (PDMS) form and placed in the envelope containing the X-ray, which is part of the travel packet. These packets are physically carried by the refugees to the United States. If the X-ray envelope is missing, the PDMS form should be placed in a separate sealed envelope inside the IOM travel bag, so that this medical information about treatment remains confidential. IOM providers should also enter the information in the Migrant Management &amp; Operational Systems Application (MiMOSA) prior to the refugees&#39; arrival, so it can be transmitted to CDC&#39;s Electronic Disease Notification (EDN) system. If treatment was not administered, this should be clearly documented, along with the reason that treatment was not administered. For children and pregnant and breastfeeding women who do not receive presumptive therapy, the need for subsequent treatment should be clearly documented.</p><h2><a class="onThisPageAnchor" id="references" name="references" title="&lt;strong&gt;References&lt;/strong&gt;"></a>References</h2><ol><li id="ref-1" name="Reference 1">Miller JM, Boyd HA, Ostrowski SR, et al. Malaria, intestinal parasites, and schistosomiasis among Barawan Somali refugees resettling to the United States: a strategy to reduce morbidity and decrease the risk of imported infections. Am J Trop Med Hyg. 2000;62:115-21.</li><li id="ref-2" name="Reference 2">Swanson SJ, Phares CR, Mamo B, et al. Albendazole treatment and enteric parasites in United States-bound refugees. N Engl J Med 2012;366:1498-507.</li><li id="ref-3" name="Reference 3">Geltman PL, Cochran J, Hedgecock C. Intestinal parasites among African refugees resettled in Massachusetts and the impact of an overseas pre-departure treatment program. Am J Trop Med Hyg. 2003;69(6):657-62.</li><li id="ref-4" name="Reference 4">Muennig P, Pallin D, Sell RL, Chan MS. The cost effectiveness of strategies for the treatment of intestinal parasites in immigrants. N Engl J Med. 1999;340(10):773-9.</li><li id="ref-5" name="Reference 5">Marti H, Haji HJ, Savioli L, et al. A comparative trial of a single-dose ivermectin versus three days of albendazole for treatment of <em>Strongyloides stercoralis</em> and other soil-transmitted helminth infections in children. Am J Trop Med Hyg. 1996;55(5):477-81.</li><li id="ref-6" name="Reference 6">Mohammed KA, Haji HJ, Gabrielli AF, et al. Triple co-administration of ivermectin, albendazole and praziquantel in Zanzibar: a safety study. PLoS Negl Trop Dis. 2008;2(1):e171.</li><li id="ref-7" name="Reference 7">World Health Organization. Preventive chemotherapy in human helminthiasis: a manual for health professionals and programme managers. 2006. Available at: <a href="http://whqlibdoc.who.int/publications/2006/9241547103_eng.pdf">http://whqlibdoc.who.int/publications/2006/9241547103_eng.pdf [PDF - 74 pages]</a>. Last accessed, August 1, 2013.</li></ol><h2><a class="onThisPageAnchor" id="table-1" name="table-1" title="&lt;strong&gt;Table 1&lt;/strong&gt;"></a>Table 1</h2>
		<div class="rx-row otable">
    	<table summary="This table lists the standard dosing for presumptive treatment of parasitic infections, sorted by refugee populations."><caption>Recommended medication regimen and standard dosing for presumptive treatment of parasitic infections</caption><thead><tr><th id="population" rowspan="2">Refugee Population</th><th colspan="3" id="regimens">Regimens by Pathogen</th></tr><tr><th headers="regimens" id="albendazole">Soil-transmitted helminths:<br />Albendazole<sup>1</sup></th><th headers="regimens" id="ivermectin">Strongyloidiasis:<br />Ivermectin<sup>1</sup></th><th headers="regimens" id="praziquantel">Schistosomiasis<sup>2</sup>:<br />Praziquantel<sup>3</sup></th></tr></thead><tbody><tr><th colspan="4" headers="population" id="adults">Adults</th></tr><tr><th headers="adults" id="ad1">Asia, Middle East, North Africa, Latin American, &amp; Caribbean</th><td headers="ad1 albendazole">400 mg orally for 1 day</td><td headers="ad1 ivermectin">Ivermectin, 200 &#181;g/kg/day orally once a day for 2 days</td><td headers="ad1 praziquantel">Not recommended</td></tr><tr><th headers="adults" id="ad2">Sub-Saharan Africa, non-<em>Loa loa</em>-endemic area</th><td headers="ad2 albendazole">400 mg orally for 1 day</td><td headers="ad2 ivermectin">Ivermectin, 200 &#181;g/kg/day orally once a day for 2 days</td><td headers="ad2 praziquantel">Praziquantel, 40 mg/kg (may be divided and given in two doses for better tolerance).</td></tr><tr><th headers="adults" id="ad3">Sub-Saharan Africa, <em>Loa loa</em>- endemic area</th><td headers="ad3 albendazole">400 mg orally for 1 day</td><td headers="ad3 ivermectin">If Loa loa cannot be excluded, treatment may be deferred until after arrival in the United States<br />-OR-<br />Albendazole 400 mg twice a day for 7 days</td><td headers="ad3 praziquantel">Praziquantel, 40 mg/kg (may be divided and given in two doses for better tolerance).</td></tr><tr><th colspan="4" headers="population" id="pregnant">Pregnant Women</th></tr><tr><th headers="pregnant" id="p1">Asia, Middle East, North Africa, Latin America &amp; Caribbean</th><td headers="p1 albendazole">Not recommended</td><td headers="p1 ivermectin">Not recommended</td><td headers="p1 praziquantel">Not applicable</td></tr><tr><th headers="pregnant" id="p2">Sub-Saharan Africa</th><td headers="p2 albendazole">Not recommended</td><td headers="p2 ivermectin">Not recommended</td><td headers="p2 praziquantel">Praziquantel, 40 mg/kg (may be divided and given in two doses for better tolerance).</td></tr><tr><th colspan="4" headers="population" id="children">Children</th></tr><tr><th headers="children" id="c1">Asia, Middle East, North Africa, Latin America &amp; Carribean</th><td headers="c1 albendazole">12-23 months of age: 200 mg orally for 1 day. Presumptive therapy is not recommended for any infant less than 12 months of age.</td><td headers="c1 ivermectin">Ivermectin, 200 &#181;g/kg/day orally once a day for 2 days<br />Should not be used presumptively if &#8804;15 kg</td><td headers="c1 praziquantel">Not applicable</td></tr><tr><th headers="children" id="c3">Sub-Saharan Africa</th><td headers="c3 albendazole">12-23 months of age: 200 mg orally for 1 day. Presumptive therapy is not recommended for any infant less than 12 months of age.</td><td headers="c3 ivermectin">Ivermectin, 200 &#181;g/kg/day orally once a day for 2 days<br />Should not be used presumptively if &#8804;15 kg or from Loa loa-endemic country.</td><td headers="c3 praziquantel">Children under &#8804; 4 years of age should not receive presumptive treatment with praziquantel. Only for children from sub-Saharan Africa</td></tr></tbody></table><ol class="table-notes"><li>Although WHO states ivermectin and albendazole may be given concurrently, it is recommended that ivermectin be taken on an empty stomach and albendazole with fatty foods.</li><li>All sub-Saharan African countries except Lesotho are considered endemic for schistosomiasis.</li><li>Praziquantel, if not co-administered, should be administered at least one day prior to either ivermectin or albendazole. Praziquantel should be taken with liquids during a meal.</li></ol>
	</div>
	  <h2><a class="onThisPageAnchor" id="table-2" name="table-2" title="&lt;strong&gt;Table 2&lt;/strong&gt;"></a>Table 2</h2>
		<div class="rx-row otable">
    	<table summary="This table lists dosing recommendations for Praziquantel and Ivermectin based on weight and tablet size."><caption>Praziquantel and ivermectin dosing based on weight and tablet size for predeparture presumptive treatment of US- bound refugees</caption><thead><tr><th id="drug">Drug and dosing</th><th id="weight">Weight (kg)</th></tr></thead><tbody><tr><th colspan="2" headers="drug" id="prazi">Praziquantel<sup>1,2</sup></th></tr><tr><td headers="drug prazi">Not recommended</td><td headers="weight prazi">&lt;15</td></tr><tr><td headers="drug prazi">1 tablet (600 mg)</td><td headers="weight prazi">15-18</td></tr><tr><td headers="drug prazi">1 &#189; tablets (900 mg)</td><td headers="weight prazi">19-25</td></tr><tr><td headers="drug prazi">2 tablets (1200 mg)</td><td headers="weight prazi">26-30</td></tr><tr><td headers="drug prazi">2 &#189; tablets (1500 mg)</td><td headers="weight prazi">31-40</td></tr><tr><td headers="drug prazi">3 tablets (1800mg)</td><td headers="weight prazi">41-50</td></tr><tr><td headers="drug prazi">4 tablets (2400 mg)</td><td headers="weight prazi">51-69</td></tr><tr><td headers="drug prazi">5 tablets (3000 mg)</td><td headers="weight prazi">&#8805;70</td></tr><tr><th colspan="2" headers="drug" id="iver">Ivermectin<sup>3</sup></th></tr><tr><td headers="drug iver">Not recommended</td><td headers="weight iver">&lt;15</td></tr><tr><td headers="drug iver">1 tablet (3 mg)</td><td headers="weight iver">15-24</td></tr><tr><td headers="drug iver">2 tablets (6 mg)</td><td headers="weight iver">25-35</td></tr><tr><td headers="drug iver">3 tablets (9 mg)</td><td headers="weight iver">36-50</td></tr><tr><td headers="drug iver">4 tablets (12 mg)</td><td headers="weight iver">51-65</td></tr><tr><td headers="drug iver">5 tablets (15 mg)</td><td headers="weight iver">66-79</td></tr><tr><td headers="drug iver">200 mcg/kg</td><td headers="weight iver">&#8805;80</td></tr></tbody></table><ol class="table-notes"><li>Better tolerated if divided into two doses</li><li>Using 600-mg praziquantel tablets</li><li>Using 3-mg ivermectin tablets</li></ol>
	</div>
	  <h2><a class="onThisPageAnchor" id="table-3" name="table-3" title="&lt;strong&gt;Table 3&lt;/strong&gt;"></a>Table 3</h2>
		<div class="rx-row otable">
    	<table summary="This table lists a sample treatment regimen for oversease presumptive treatment of parasites and malaria for 3 days, with doses administered in the morning and evening."><caption>Sample 3-Day Combined Regimen for overseas presumptive treatment of parasites and malaria</caption><thead><tr><th scope="col">Presumptive Tx Day</th><th scope="col">Morning</th><th scope="col">Evening*</th></tr></thead><tbody><tr><td>Day 1</td><td>Pregnancy Test<br />Praziquantel #1<br />Artemether-lumefantrine #1</td><td>Praziquantel #2*<br />Artemether-lumefantrine 2*</td></tr><tr><td>Day 2</td><td>Ivermectin #1<br />Artemether-lumefantrine #3</td><td>Artemether-lumefantrine #4</td></tr><tr><td>Day 3</td><td>Albendazole<br />Ivermectin #2<br />Artemether-lumefantrine #5</td><td>Artemether-lumefantrine #6</td></tr></tbody></table><p class="table-notes">*On the first day, praziquantel and artemether-lumefantrine should be administered 8 hours following initial dose; on days 2 and 3 should be administered twice a day, morning and evening.</p>
	</div>
	  <h2><a class="onThisPageAnchor" id="box-1" name="box-1" title="&lt;strong&gt;Box 1&lt;/strong&gt;"></a>Box 1</h2>
		<div class="rx-row otable">
    	<table summary="This table lists African countries that are and are not considered endemic for Loa loa"><caption>Endemicity of <em>Loa loa</em> in African countries</caption><thead><tr><th scope="col"><strong>African countries NOT considered endemic for <em>Loa loa</em></strong> (may use presumptive ivermectin for <em>Strongyloides</em>)</th><th scope="col"><strong>African countries considered endemic for <em>Loa loa</em></strong> (presumptive ivermectin should <em>not</em> be used for <em>Strongyloides</em>)</th></tr></thead><tbody><tr><td>Algeria<br />Botswana<br />Burkina Faso<br />Burundi<br />C&#244;te d&#39;Ivoire<br />Egypt<br />Ethiopia<br />Eritrea<br />Gambia<br />Ghana<br />Guinea<br />Guinea-Bissau<br />Kenya<br />Liberia<br />Libya<br />Madagascar<br />Malawi<br />Mali<br />Mauritania<br />Mauritius<br />Morocco<br />Mozambique<br />Namibia<br />Niger<br />Rwanda<br />Senegal<br />Sierra Leone<br />Somalia<br />South Africa<br />Sudan<br />Swaziland<br />Tanzania<br />Togo<br />Uganda<br />Zambia<br />Zimbabwe</td><td>Angola<br />Cameroon<br />Central Africa Republic<br />Chad<br />Republic of Congo<br />Democratic Republic of the Congo<br />Equatorial Guinea<br />Gabon<br />Nigeria<br />South Sudan</td></tr></tbody></table><p class="table-notes">Zour&#233; HGM, Wanji S, Noma M, Amazigo UV, et al. (2011) The Geographic Distribution of <em>Loa loa</em> in Africa: Results of Large-Scale Implementation of the Rapid Assessment Procedure for Loiasis (RAPLOA). PLoS Negl Trop Dis 5(6): e1210. doi:10.1371/journal.pntd.0001210<br /><a href="http://www.plosntd.org/article/info:doi/10.1371/journal.pntd.0001210">http://www.plosntd.org/article/info:doi/10.1371/journal.pntd.0001210</a></p>
	</div>
	   																</div>
																</div>
										                                                                                																											                                           					</div>
					
					<div id="linkPolicy"> </div> 					
				<!-- /end #content-main-->
				</div>
				
			<!-- /end #content-inner -->
			</div>
			
			<!--RIGHT COLUMN STARTS HERE-->
			<div id="content-secondary">
				
				<div class="pageOptions">
					<div class="pageOptions-inner">
						

<ul id="services" class="services">
<li class="print"><a href="javascript:window.print();" title="Print page.">Print page</a></li>
</ul>

						


<!-- EMPTY SSI -->

																										</div>
				</div>
				 				


<!-- EMPTY SSI -->

				


<!-- EMPTY SSI -->

				


<div id="contact-info"><h5>Contact Us:</h5><ul class="noBullet"><li class="mail">Centers for Disease Control and Prevention<br /> 1600 Clifton Rd<br /> Atlanta, GA 30333</li><li class="phone">800-CDC-INFO<br /> (800-232-4636)<br /> TTY: (888) 232-6348</li><li><a href="../../../cdc-info/requestform.html">Contact CDC&#8211;INFO</a></li></ul></div>

			</div>
			<!--LEFT NAVIGATION STARTS HERE-->
			<div id="nav-container">
				 <div id="nav">
					



<h3><a href="../../index.html">Immigrant and Refugee Health</a></h3>

<ul id="nav-primary">
<li><a href="../../about-refugees.html">About Refugees</a></li>

<li><a href="../../exams/medical-examination.html">Medical Examination of Immigrants and Refugees</a>
<ul>
<li><a href="../../exams/ti/index.html">Technical Instructions</a></li>

<li><a href="../../exams/adoptees-tuberculosis-screening-faq.html">International Adoptees: Tuberculosis Screening FAQs</a></li>

<li><a href="../../exams/medical-examination-faqs.html">Frequently Asked Questions</a></li>

<li><a href="../../exams/diseases-vaccines-included.html">Diseases and Vaccines Included</a></li>

<li><a href="../../exams/medical-waivers.html">Medical Waivers</a></li>
</ul>
</li>

<li><a href="../../../panelphysicians/index.html">Panel Physician Portal</a></li>

<li><a href="../../adoption/index.html">International Adoption</a>
<ul>
<li><a href="../../adoption/before-travel.html">Before you Travel Overseas</a></li>

<li><a href="../../adoption/overseas-exam.html">Overseas Medical Exam and Vaccinations</a></li>

<li><a href="../../adoption/class-a-conditions.html">Class A Conditions / Waiver Process</a></li>

<li><a href="../../adoption/finding-doctor.html">Finding a Medical Provider in the U.S.</a></li>

<li><a href="../../adoption/goals.html">CDC's International Adoption Goals</a></li>

<li><a href="../../adoption/resources.html">Links to Other Resources</a></li>
</ul>
</li>

<li><a href="../refugee-guidelines.html">Refugee Health Guidelines</a>
<ul>
<li><a href="../domestic/domestic-guidelines.html">Domestic Guidelines</a>
<ul>
<li><a href="../domestic/checklist.html">Checklist</a></li>

<li><a href="../domestic-refugee-questions.html">FAQs: Refugee Health Program</a></li>

<li><a href="../domestic/guidelines-development.html">Guidelines Development</a></li>

<li><a href="../general-guidelines.html">General Guidelines</a></li>

<li><a href="../domestic/guidelines-history-physical.html">Guidelines for the History and Physical</a></li>

<li>
	<a href="../domestic/hepatitis-screening-guidelines.html">Hepatitis Screening Guidelines</a>
</li>

<li><a href="../domestic/screening-hiv-infection-domestic.html">HIV Infection Screening Guidelines</a></li>

<li><a href="../domestic/immunizations-guidelines.html">Immunizations Guidelines</a></li>

<li><a href="../domestic/intestinal-parasites-domestic.html">Intestinal Parasite Guidelines</a></li>

<li><a href="../lead-guidelines.html">Lead Screening Guidelines</a></li>

<li><a href="../domestic/malaria-guidelines-domestic.html">Malaria Guidelines</a>
<ul>
<li><a href="../domestic/malaria-guidelines-domestic-fig1.html">Figure 1. Region of Origin of United States Refugees</a></li>
</ul>
</li>

<li><a href="../domestic/mental-health-screening-guidelines.html">Mental Health Screening Guidelines</a></li>

<li><a href="../domestic/nutrition-growth.html">Nutrition and Growth Guidelines</a></li>

<li>
	<a href="../domestic/sexually-transmitted-diseases/index.html">Sexually Transmitted Diseases Guidelines</a>
</li>

<li><a href="../domestic/tuberculosis-guidelines.html">Tuberculosis Guidelines</a></li>
</ul>
</li>

<li><a href="overseas-guidelines.html">Overseas Guidelines</a>
<ul>
<li><a href="malaria-guidelines-overseas.html">Malaria Guidelines</a></li>

<li><a href="intestinal-parasites-overseas.html">Intestinal Parasite Guidelines</a></li>
</ul>
</li>

<li>
<a href="interventions/index.html">Overseas Interventions</a>
<ul>
<li>
<a href="interventions/interventions.html">Treatment Schedules for Presumptive Parasitic Infections</a></li>

<li>
<a href="interventions/immunizations-schedules.html">Vaccination Program for U.S.-Bound Refugees</a></li>
</ul>
</li>
</ul>
</li>

<li><a href="../../profiles/index.html">Refugee Health Profiles</a></li>

<li><a href="../../laws-regulations.html">Laws and Regulations</a>
<ul>
<li>
		<a href="../../laws-regs/revisions-medical-screening/medical_examination_aliens.html">Final Rule: Revisions to Medical Screening Process</a>
	
<ul>
<li>
		<a href="../../laws-regs/revisions-medical-screening/faq.html">Frequently Asked Questions</a>
	</li>

<li>
		<a href="../../laws-regs/revisions-medical-screening/index.html">Notice of Proposed Rule</a>
	</li>

<li>
		<a href="../../laws-regs/revisions-medical-screening/frequently-asked-questions.html">Proposed Rule Frequently Asked Questions</a>
	</li>
</ul>
</li>

<li><a href="../../laws-regs/hiv-ban-removal/final-rule.html">Final Rule: Removal of HIV Entry Ban</a>
<ul>
<li><a href="../../laws-regs/hiv-ban-removal/final-rule-general-qa.html">General Questions and Answers</a></li>

<li><a href="../../laws-regs/hiv-ban-removal/final-rule-technical-qa.html">Technical Questions and Answers</a></li>

<li><a href="../../laws-regs/hiv-ban-removal/hivecon-model.html">HIVEcon Model</a></li>

<li><a href="../../laws-regs/hiv-ban-removal/index.html">Proposed Removal of HIV Entry Ban</a>
<ul>
<li><a href="../../laws-regs/hiv-ban-removal/fact-sheet.html">Fact Sheet</a></li>

<li><a href="../../laws-regs/hiv-ban-removal/qa-general.html">General Questions and Answers</a></li>

<li><a href="../../laws-regs/hiv-ban-removal/qa-technical.html">Technical Questions and Answers</a></li>
</ul>
</li>
</ul>
</li>

<li><a href="../../laws-regs/vaccination-immigration/revised-vaccination-criteria-immigration.html">Revised Vaccination Criteria for U.S. Immigration</a>
<ul>
<li><a href="../../laws-regs/vaccination-immigration/revised-vaccination-immigration-faq.html">Frequently Asked Questions (FAQs)</a></li>

<li><a href="../../laws-regs/vaccination-immigration/proposed-vaccination-criteria-immigration.html">Proposed Vaccination Criteria for U.S. Immigration</a>
<ul>
<li><a href="../../laws-regs/vaccination-immigration/fact-sheet.html">Fact Sheet</a></li>
</ul>
</li>
</ul>
</li>

<li>
	<a href="../../laws-regs/ifr/final-rule.html">Interim Final Rule Revising Medical Examination of Aliens (42 CFR Part 34)</a>

<ul>
<li>
	<a href="../../laws-regs/ifr/final-rule-questions.html">Frequently Asked Questions</a>
</li>

<li>
	<a href="../../laws-regs/ifr/final-rule-comments.html">View Public Comments</a>
</li>
</ul>
</li>
</ul>
</li>

<li><a href="../../resources/index.html">Immigrant and Refugee Resources</a></li>

<li><a href="../../migrant-serum-bank.html">Migrant Serum Bank</a></li>
</ul>


				 </div> 
				 <div class="bottom"></div> 
				



<div class="related">
<div class="inner">
<h4><span>Related Links</span></h4>

<ul>
<li>
<a href="../../exams/ti/index.html">Technical Instructions for Panel Physicians and Civil Surgeons</a></li>

<li>
<a href="../../../usmexicohealth/index.html">United States-Mexico Public Health</a></li>

<li>
<a href="https://www.cdc.gov/globalhealth/index.html">Global Health</a></li>

<li>
	<a href="../../../globalhealth/healthprotection/index.html">Global Health Protection and Security</a>
</li>

<li class="last"><a href="https://www.cdc.gov/ncezid/dgmq/index.html">Division of Global Migration and Quarantine</a></li>
</ul>
</div>

<div class="bot"><!-- --></div>
</div>


			</div>			
		</div>
		
		<div class="preFoot">
			<div id="plugin-legend"><h3>File Formats Help:</h3><ul><li class="plugin-pdf"><a href="../../../Other/plugins/index.html#pdf"><img alt="Adobe PDF file" src="../../../TemplatePackage/images/icon_pdf.gif" /></a></li><li class="plugin-word"><a href="../../../Other/plugins/index.html#doc"><img alt="Microsoft Word file" src="../../../TemplatePackage/images/icon_word.gif" /></a></li><li class="plugin-excel"><a href="../../../Other/plugins/index.html#xls"><img alt="Microsoft Excel file" src="../../../TemplatePackage/images/icon_excel.gif" /></a></li><li class="plugin-ppt"><a href="../../../Other/plugins/index.html#ppt"><img alt="Microsoft PowerPoint file" src="../../../TemplatePackage/images/icon_ppt.gif" /></a></li><li class="plugin-wmv"><a href="../../../Other/plugins/index.html#wmv"><img alt="Audio/Video file" src="../../../TemplatePackage/images/icon_wmv.gif" /></a></li><li class="plugin-zip"><a href="../../../Other/plugins/index.html#zip"><img alt="Zip Archive file" src="../../../TemplatePackage/images/icon_zip.gif" /></a></li><li class="plugin-real"><a href="../../../Other/plugins/index.html#ram"><img alt="RealPlayer file" src="../../../TemplatePackage/images/icon_real.gif" /></a></li><li class="plugin-qt"><a href="../../../Other/plugins/index.html#qt"><img alt="Apple Quicktime file" src="../../../TemplatePackage/images/icon_qt.gif" /></a></li></ul><p><a href="../../../Other/plugins/index.html"><span class="tp-label">How do I view different file formats (PDF, DOC, PPT, MPEG) on this site?</span> <img alt="double arrows." src="../../../TemplatePackage/images/btn_dblArrows.gif" /></a></p></div> 			<div class="pageOptions-horizontal">
				<ul class="services">
				

<li class="print"><a href="javascript:window.print();">Print</a></li>

				</ul>
				




							</div>
			<div id="datestamp">
				<ul>
																<li class="last-reviewed">Page last reviewed: <span>October 25, 2013</span></li>
																<li class="last-updated">Page last updated: <span>October 25, 2013</span></li>
																				
					
				</ul>
				


<ul class="noindent"><li class="content-source">Content source: <a href="../../../index.html">Centers for Disease Control and Prevention</a><br /><a href="../../../ncezid/dw-index.html">National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)</a><br /><a href="https://www.cdc.gov/ncezid/dgmq/index.html">Division of Global Migration and Quarantine (DGMQ)</a></li></ul>

			</div>
		</div>
		



<div id="siteinfo">
<div id="siteinfo-nav">
<ul class="menu">
<li><a href="../../../index.html">Home</a></li>

<li><a href="../../../az/a.html">A-Z Index</a></li>

<li><a href="../../../Other/policies.html">Policies</a></li>

<li><a href="../../../Other/about_cdcgov.html">Using this Site</a></li>

<li><a href="../../../Other/link.html">Link to Us</a></li>

<li><a href="../../../socialmedia/index.html">Social Media</a></li>

<li class="last-child"><a href="../../../contact/index.html">Contact CDC</a></li>
</ul>
</div>

<div id="siteinfo-credits">
<div id="siteinfo-logos"><a href="http://www.usa.gov/"><img alt="USA.gov: The U.S. Government's Official Web Portal" border="0" height="55" id="logo_usagov" src="../../../TemplatePackage/images/logo_usagov.gif" width="188" /></a><a href="http://www.hhs.gov/"><img alt="Department of Health and Human Services" border="0" height="55" id="logo_dhhs" src="../../../TemplatePackage/images/logo_dhhs.gif" width="61" /></a></div>

<address>Centers for Disease Control and Prevention &#160; 1600 Clifton Rd. Atlanta, GA 30329-4027, USA<br />
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - <a href="../../../info.html">Contact CDC-INFO</a></address>
</div>
</div>


		



		 		



		<div id="AZlist-container"><a id="az" name="az"></a><span>A-Z Index</span> <ol class="AZlist"><li><a href="../../../az/a.html">A</a></li><li><a href="../../../az/b.html">B</a></li><li><a href="../../../az/c.html">C</a></li><li><a href="../../../az/d.html">D</a></li><li><a href="../../../az/e.html">E</a></li><li><a href="../../../az/f.html">F</a></li><li><a href="../../../az/g.html">G</a></li><li><a href="../../../az/h.html">H</a></li><li><a href="../../../az/i.html">I</a></li><li><a href="../../../az/j.html">J</a></li><li><a href="../../../az/k.html">K</a></li><li><a href="../../../az/l.html">L</a></li><li><a href="../../../az/m.html">M</a></li><li><a href="../../../az/n.html">N</a></li><li><a href="../../../az/o.html">O</a></li><li><a href="../../../az/p.html">P</a></li><li><a href="../../../az/q.html">Q</a></li><li><a href="../../../az/r.html">R</a></li><li><a href="../../../az/s.html">S</a></li><li><a href="../../../az/t.html">T</a></li><li><a href="../../../az/u.html">U</a></li><li><a href="../../../az/v.html">V</a></li><li><a href="../../../az/w.html">W</a></li><li><a href="../../../az/x.html">X</a></li><li><a href="../../../az/y.html">Y</a></li><li><a href="../../../az/z.html">Z</a></li><li><a href="../../../az/0.html">#</a></li></ol></div> 	<!-- /end #wrapper-inner -->
	</div>
<!-- /end #wrapper -->
</div>
<!-- xxxxxxxxxxxxxxxxxx METRICS code begins here xxxxxxxxxxxxxxxxxxxxxxxxxxx-->
<div id="metrics">

<!-- Begin Google Analytics Code -->
<script type="text/javascript" src="../../../JScript/metrics/google/google-cdc-a.js"></script>
<!-- End Google Analytics Code -->

<!-- SiteCatalyst code version: H.21. -->
<script language="JavaScript" type="text/javascript" src="../../../JScript/metrics/topic_levels.js"></script>
<script language="JavaScript" type="text/javascript" src="../../../JScript/metrics/s_code_v21_cdcgov.js"></script>
<script language="JavaScript" type="text/javascript">






    s.pageName=document.title;
    s.channel="immigrantrefugeehealth";
    siteCatalyst.setLevel1("NCEZID"); 
    siteCatalyst.setLevel2("DGMQ"); 
    siteCatalyst.setLevel3("Immigrant and Refugee Health"); 
    siteCatalyst.setLevel4("Refugee Health Guidelines"); 
    






s.prop2=window.location.href;
s.prop26=document.title;
s.prop30=document.title;
s.prop31=window.location.href;
s.prop46=window.location.href;
s.server=window.location.hostname;

// Update the level variables here.
updateVariables(s);

/************* DO NOT ALTER ANYTHING BELOW THIS LINE ! **************/
var s_code=s.t();if(s_code)document.write(s_code);//--></script>
<script language="JavaScript" type="text/javascript"><!--
if(navigator.appVersion.indexOf('MSIE')>=0)document.write(unescape('%3C')+'\!-'+'-');
//--></script><noscript><a href="http://www.omniture.com" title="Web Analytics"><img
src="http://mtrics.cdc.gov/b/ss/cdcgov/1/H.21--NS/0"
height="1" width="1" border="0" alt="Web Analytics" /></a></noscript><!--/DO NOT REMOVE/-->
<!-- End SiteCatalyst code version: H.21. -->
<!-- Begin Google Analytics Code -->
<script type="text/javascript" src="../../../JScript/metrics/google/google-cdc-c.js"></script>
<!-- End Google Analytics Code -->
</div>
<!-- xxxxxxxxxxxxxxxxxx METRICS code ends here xxxxxxxxxxxxxxxxxxxxxxxxxxx-->


</body>
</html>	
